Olanzapine drives Dr Reddy's business in third quarter PMLiVE Dr Reddy's is also starting to build a portfolio of biosimilars in emerging markets - including arthritis treatment rituximab and filgrastim - which could add $100m in revenues in the next two to three years. Generic revenues rose 57 per cent to $402m, ... |
